Moreover, the FDA recently approved the combination of encorafenib with binimetinib for metastatic NSCLC harboring the BRAF V600E mutation, with clinical trials demonstrating its notable effectiveness in NSCLC treatment [68]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.